Publications by authors named "Tomas Haas"

Claim this Profile
R
Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for V600-Mutant Unresectable or Metastatic Melanoma.
Reinhard Dummer, Georgina V Long, Caroline Robert, Hussein A Tawbi, Keith T Flaherty, Tomas Haas

J Clin Oncol· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials.
Axel Hauschild, Paolo A Ascierto, Dirk Schadendorf, Jean Jacques Grob, Antoni Ribas, Tomas Haas

Eur J Cancer· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to E. Hindié and K.R. Hess.
Georgina V Long, Reinhard Dummer, Dirk Schadendorf, Mario Santinami, Victoria Atkinson, Tomas Haas

J Clin Oncol· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected V600-Mutant Stage III Melanoma.
Axel Hauschild, Reinhard Dummer, Dirk Schadendorf, Mario Santinami, Victoria Atkinson, Tomas Haas

J Clin Oncol· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis.
Jennifer L McQuade, Carrie R Daniel, Kenneth R Hess, Carmen Mak, Daniel Y Wang, Tomas Haas

Lancet Oncol· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Everolimus and sunitinib for advanced pancreatic neuroendocrine tumors: a matching-adjusted indirect comparison.
James Signorovitch, Elyse Swallow, Evan Kantor, Xufang Wang, Judith Klimovsky, Tomas Haas

Exp Hematol Oncol· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases.
David Lebwohl, Ozlem Anak, Tarek Sahmoud, Judith Klimovsky, Ingrid Elmroth, Tomas Haas

Ann N Y Acad Sci· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-reported outcomes in a phase iii study of everolimus versus placebo in patients with metastatic carcinoma of the kidney that has progressed on vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy.
Jennifer L Beaumont, Zeeshan Butt, Jeanfrancois Baladi, Robert J Motzer, Tomas Haas

Oncologist· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Everolimus for advanced pancreatic neuroendocrine tumors.
James C Yao, Manisha H Shah, Tetsuhide Ito, Catherine Lombard Bohas, Edward M Wolin, Tomas Haas

N Engl J Med· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial.
James C Yao, Catherine Lombard-Bohas, Eric Baudin, Larry K Kvols, Philippe Rougier, Tomas Haas

J Clin Oncol· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Standard surgical versus percutaneous dilatational tracheostomy in intensive care patients.
Jindrich Lukas, Jaroslava Duskova, David Lukas, Jan Paska, Martin Stritesky, Tomas Haas

Saudi Med J· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
1
12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients.
Helio Tedesco-Silva, Stefan Vitko, Julio Pascual, Josette Eris, John C Magee, Tomas Haas

Transpl Int· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral fingolimod (FTY720) for relapsing multiple sclerosis.
Ludwig Kappos, Jack Antel, Giancarlo Comi, Xavier Montalban, Paul O'Connor, Tomas Haas

N Engl J Med· September 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of 645 patients with primary hyperparathyroidism with special references to cholelithiasis.
Petr Don Broulik, Tomas Haas, Svaiopiak Adámek

Intern Med· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of atorvastatin on non-cholesterol sterols in patients with type 2 diabetes mellitus and cardiovascular disease.
Alena Smahelová, Radek Hyspler, Tomás Haas, Alena Tichá, Vladimír Bláha

Pharmacol Res· January 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study.
Björn Nashan, John Curtis, Claudio Ponticelli, Georges Mourad, Jonathan Jaffe, Tomas Haas

Transplantation· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Repeatability of noninvasive surrogates of endothelial function.
Jan Malik, Dan Wichterle, Tomas Haas, Vojtech Melenovsky, Jan Simek

Am J Cardiol· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies.
Stefan Vitko, Helio Tedesco, Josette Eris, Julio Pascual, John Whelchel, Tomas Haas

Am J Transplant· April 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of the insulin action parameters from hyperinsulinemic clamps with homeostasis model assessment and QUICKI indexes in subjects with different endocrine disorders.
Jan Skrha, Tomás Haas, Gustav Sindelka, Martin Prázný, Jirí Widimský

J Clin Endocrinol Metab· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of atorvastatin and fenofibrate on autonomic tone in subjects with combined hyperlipidemia.
Vojtech Melenovsky, Dan Wichterle, Jan Simek, Jan Malik, Tomas Haas

Am J Cardiol· August 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of folic acid on fenofibrate-induced elevation of homocysteine and cysteine.
Vojtech Melenovsky, Tomas Stulc, Viktor Kozich, Barbora Grauova, Jakub Krijt, Tomas Haas

Am Heart J· July 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intima-media thickness of the common carotid artery is the significant predictor of angiographically proven coronary artery disease.
Robert Holaj, Jiri Spacil, Jan Petrasek, Jan Malik, Tomas Haas

Can J Cardiol· May 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Soluble leptin receptor levels in patients with anorexia nervosa.
Jarmila Krizova, Hana Papezova, Denisa Haluzikova, Jitka Parizkova, Jan Jiskra, Tomas Haas

Endocr Res· August 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis